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Background: Limited information is available regarding the clinical usefulness of measuring the levels of
IgE to allergen components from house dust mites (HDMs) in the diagnosis of genuine HDM allergy.
Methods: To evaluate the diagnostic usefulness of measuring levels of serum IgE antibodies (Abs) to
allergen components from Dermatophagoides pteronyssinus (DP) as a predictor of immediate asthmatic
response (IAR) to bronchoprovocation, we studied 55 DP-sensitized asthmatic patients who underwent a
bronchoprovocation test using crude DP extract. The levels of IgE Abs to crude DP, nDer p 1, rDer p 2, and
rDer p 10 in patients who showed IAR (n ¼ 41) were compared with those in patients who showed no
IAR (n ¼ 14).
Results: While the frequencies of positivity for IgE Abs to nDer p 1 and rDer p 2 among the entire study
population were 89 and 86%, respectively, all patients with IAR tested positive for both of themwith high
IgE concentrations. The areas under the receiver operating characteristic curves for IgE to nDer p 1 and
rDer p 2 as predictors of IAR were 0.913 and 0.906, respectively. The speciﬁcity of IgE to nDer p 1 and
rDer p 2 was higher than IgE to crude DP even at low cut-off points.
Conclusions: IgE to nDer p 1 and/or rDer p 2 was highly predictive of allergen-induced IAR. These
ﬁndings validate the clinical usefulness of measuring the levels of IgE to nDer p 1 and rDer p 2 as a
diagnostic tool for genuine HDM allergy.
Copyright © 2014, Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.Introduction
Housedustmites (HDMs) are among themost important allergen
sources worldwide.1,2 While many different species of HDM have
been reported to occur in indoor environments, Dermatophagoidesr Allergy and Rheumatology,
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rgology. Production and hosting by Elspteronyssinus (DP) and Dermatophagoides farinae (DF) are the most
important species in the development of HDM allergy. Epidemio-
logical studies have shown a high correlation of exposure and
sensitization toHDMswith the developmentof bronchial asthma.3e5
On the other hand, it is well recognized that not all the patients who
are sensitized to HDMs develop clinical symptoms of HDM allergy.
Additionally, the clinical relevance of sensitization to crude DP
extract is not always clear, particularly for multisensitized patients.
This is sometimes a problem in clinical settings when allergen-
speciﬁc immunotherapy using DP extract is considered.evier B.V. All rights reserved.
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of IgE-mediated allergy. However, regarding HDM allergy, the
reliability of case history is not always high6; namely, self-reported
hypersensitivity symptoms after house dust exposure may not
necessarily identify HDM as the actual trigger of symptoms. One
possible reason for this is that most patients are not able to
recognize the presence of HDMs in their indoor environment.
Additionally, HDMs usually coexist with other arthropods, such as
storage mites,7,8 booklice,9,10 or cockroaches, pet dander, or mold
spores.11 It is generally considered that an immediate asthmatic
response (IAR) after the bronchoprovocation (BP) using allergen
aerosols is a more reliable marker for the diagnosis of clinically
relevant allergen-speciﬁc reactivity in patients with asthma than a
positive case history in sensitized individuals.12,13
To date, measurement of serum IgE antibodies (Abs) to crude
extract and/or the skin prick test using crude extract has been
performed as a standard test for allergy diagnosis in combination
with case history. However, studies have shown that some allergen
components from crude DP extract, such as tropomyosin,14,15
arginine kinase,16 and glutathione S-transferase,17 can contribute
to cross-reactivity between crude DP extract and extracts from
other invertebrates. Therefore, sensitization to crude DP extract
does not always indicate genuine HDM sensitization. Currently,
allergen components puriﬁed from their native sources or pro-
duced as recombinant proteins have been introduced into the
battery of tests available for the diagnosis of allergic diseases,18e21
which is generally called component-resolved diagnostics
(CRD),22e26 or recently called molecular-based allergy diagnosis.27
Such techniques and diagnostics may solve these problems; how-
ever, there have been few CRD studies on HDM allergy.28e30
In the World Health Organization and International Union of
Immunological Societies (WHO/IUIS) Allergen Nomenclature
database,31 17 allergenic proteins from DP have been registered.
Among these proteins, it is possible to measure the levels of IgE Abs
to native Der p 1 (nDer p 1), recombinant Der p 2 (rDer p 2), and
rDer p 10 using the commercially available ImmunoCAP system
(Thermo Fisher Scientiﬁc, Uppsala, Sweden). Der p 1 and Der p 2 are
the major allergens classiﬁed into Group 1 allergens (Der p 1, Der f
1) and Group 2 allergens (Der p 2, Der f 2), respectively. The Group 1
allergens Der p 1 and Der f 1 are allergenic proteins of 24 kDa
sharing 80% amino acid sequence identity and a biochemical
function as cysteine proteases.32 The Group 2 allergens (Der p 2 and
Der f 2) also show high cross-reactivity with each other.33 Owing to
the strong cross-reactivity between major allergens from DP and
DF, sensitization to Der p 1 and/or Der p 2 is considered as a marker
of sensitization to mites of the genus Dermatophagoides. Evaluating
the sensitization to Der p 1 and/or Der p 2 is considered important
for the selection of patients suitable for allergen immunotherapy
using HDM extract.29 Der p 10 (tropomyosin) is a minor allergen in
HDMs, but it is highly responsible for cross-reactivity between
different HDM species and other invertebrates.
The aim of this study was to evaluate the clinical usefulness of
measuring the levels of IgE Abs to commercially available allergen
components from DP in the diagnosis of clinically relevant HDM al-
lergy among asthmatic patients. We considered IAR after BP as a
reliable indicator of genuine HDM allergy, and compared challenge
outcomewith the levels of IgEAbs to nDerp 1, rDer p 2, and rDer p 10.
Methods
Patients
We studied 55 adult asthma patients sensitized to crude DPwho
visited the Allergology Department of Sagamihara National Hos-
pital and underwent BP using DP aerosol between 2000 and 2009.All the patients studied showed positive results in the skin test and/
or the test for serum speciﬁc IgE Abs to DP (ImmunoCAPR, Allergen
d1). Indications for the BP using allergen aerosol for each patient
were determined by their physicians according to the clinical ne-
cessity. In most cases, patients underwent BP to conﬁrm the airway
reactivity to DP before starting allergen immunotherapy using DP
extract. Patients being treated with systemic corticosteroids, pre-
viously treated with allergen immunotherapy using any allergen
extract, or with an upper or lower tract respiratory infection in the
previous month were excluded from the study. All the patients
recruited to the study were considered as having mild to moderate
persistent asthma on the basis of the Global Initiative for Asthma
2012 guidelines.34 Written informed consent was obtained from all
the patients included in the study. The ethics committee of Saga-
mihara National Hospital approved the study protocol.
Bronchoprovocation test
The BP with aqueous DP extracts (HollisterStier, Washington,
USA), which was the same as extract used for skin test, was per-
formed by the 2-min tidal breathing method.35 Forced expiratory
volume in 1 s (FEV1) was determined and recorded using the same
spirometer in all the subjects. All medications were withheld for at
least 24 h before the start of the study until the end of the study
period. The patients inhaled a solution in a DeVilbiss nebulizer
(DeVilbiss, Somerset, Pa) operated using compressed air at a ﬂow
rate of 5 L/min. The nose was clipped and aerosols were inhaled
through a mouthpiece during tidal breathing. After the measure-
ment of baseline FEV1, patients inhaled an allergen diluent for
2 min. When no change in FEV1 was observed, allergen inhalation
was performed. The diluted allergen extract was inhaled for 2 min,
and FEV1 was measured 10 min after each inhalation. The allergen
was administered at increasing concentrations (10, 100, 500, and
1000 AU/ml). The inhalation test was stopped when an IAR
occurred, which was deﬁned as a decrease in FEV1 of at least 20%
from baseline within 20 min after allergen inhalation.
Serological analysis
Serum samples were obtained from patients before the BP and
were stored at 20 C until assay. The levels of serum speciﬁc IgE
Abs to crude DP, nDer p 1, rDer p 2, and rDer p 10 were determined
using a commercially available ImmunoCAP system (Thermo Fisher
Scientiﬁc, Uppsala, Sweden; allergen codes, d1, d202, d203, and
d205). The sum of the levels of IgE Abs to nDer p 1 and that to rDer p
2were also calculated and described as “nDer p 1þ rDer p 2” in this
manuscript. A level of IgE Abs0.35 kUA/L was regarded as positive
according to the manufacturer's recommendation. The levels of IgE
Abs lower than 0.35 kUA/L detection limit were assigned a value of
0.34 kUA/L in the statistical analysis.
Statistical analyses
The patients were divided into two groups according to the
development of IAR, and the levels of speciﬁc IgE Abs were
compared between the groups. Receiver operating characteristic
(ROC) curves as a predictor of IAR positivity were plotted for the
levels of IgE Abs to crude DP, nDer p 1, rDer p 2, and rDer p 10
separately, and the area under each ROC curve (AUC) was calcu-
lated. The quantitative relationship between the logarithm of levels
of IgE Abs and challenge outcome was analyzed using logistic
regression.36 Fitted predicted probability curves were plotted using
the results from the logistic regression analysis. To explore the
diagnostic value of the levels of IgE Abs to allergens at different cut-
off points, sensitivity and speciﬁcity were calculated from two-by-
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These cut-off points were determined in accordance with the
classiﬁcation recommended by the manufacturer, namely, class 0,
less than 0.35 kUA/L; class 1, 0.35 e <0.7 kUA/L; class 2, 0.70 e
<3.5 kUA/L; class 3, 3.50 e <17.5 kUA/L; class 4, 17.5 e <50 kUA/L;
class 5, 50 e 100 kUA/L; and class 6, >100 kUA/L.
The collected data were analyzed using SPSS ver. 21.0 (IBM,
Tokyo, Japan). Spearman's rank correlation test was performed to
determine the coefﬁcient of correlation between different IgE test
results. The statistical signiﬁcance of differences between the
continuous variables studied was analyzed by the ManneWhitney
U-test. The chi-square test was used to determine whether distri-
butions of categorical variables signiﬁcantly differed from each
another. A p value of 0.05 or less was considered statistically
signiﬁcant.Fig. 1. Levels of IgE Abs to crude DP, nDer p 1, rDer p 2, and rDer p 10 in sera from IAR-
positive and IAR-negative patients. *p < 0.01. The number of patients showing negative
results in each set of measurements is indicated below the dotted cut-off line
(0.35 kUA/L).Results
All patients except one were positive for IgE Abs to crude DP.
One single patient tested negative for IgE to crude DP but positive in
the skin test. The frequencies of positivity for IgE Abs to allergen
components from DP were as follows: nDer p 1, 89%; rDer p 2, 86%;
and rDer p 10, 6%.
Forty-one patients showed IAR and 14 showed no IAR in the BP.
Table 1 shows the characteristics of patients with and without IAR.
Age and total serum IgE level differed signiﬁcantly between these
groups. Fig. 1 shows levels of IgE Abs to crude DP, nDer p 1, rDer p 2,
and rDer p 10 in sera from IAR-positive and IAR-negative patients.
All the IAR-positive patients were positive for IgE Abs to crude DP,
nDer p 1, and rDer p 2. The levels of IgE Abs to crude DP, nDer p 1
and rDer p 2, but not to rDer p 10, were signiﬁcantly higher in the
IAR-positive patients than in the IAR-negative patients.
The levels of IgE Abs to nDer p 1 and rDer p 2 correlated closely
with those to crude DP (nDer p 1-crude DP; R¼ 0.99, p < 0.001, rDer
p 2-crude DP; R ¼ 0.97, p < 0.001) (Fig. 2A, B). All patients whose
level of IgE Abs to crude DP  3.5 kUA/L (n ¼ 43) were positive for
IgE Abs to both nDer p 1 and rDer p 2. In contrast, among thosewith
levels of IgE Abs to crude DP < 3.5 kUA/L (n ¼ 12), 6 (50%) tested
negative to both nDer p 1 and rDer p 2. None of these 6 patients
showed a positive IAR. There was no signiﬁcant correlation be-
tween the levels of IgE Abs to rDer p 10 and crude DP (R ¼ 0.17,
p ¼ 0.225) (Fig. 2C). However, there was a strong correlation be-
tween the levels of IgE Abs to nDer p 1 and rDer p 2 (R ¼ 0.95,
p < 0.001) (Fig. 2D). As shown in Fig. 2A and B, the levels of IgE Abs
were higher to crude DP extract than to either of nDer p 1 and rDer
p 2 in most cases. However, the sum of IgE levels to nDer p 1 and
rDer p 2 was similar to the level of IgE Abs to crude DP extract
(Fig. 2E), demonstrating that both Der p 1 and Der p 2 are major
allergenic determinants in HDM.
ROC analysis was performed to evaluate the ability of IgE Abs to
crude DP and pure DP components to predict IAR (Fig. 3A). TheTable 1
Characteristics of patients with and without IAR after bronchoprovocation with DP
aerosol.
IAR-positive (n ¼ 41) IAR-negative (n ¼ 14) p-Value
Age (yr) 31 (26e39) 46 (32e58) 0.02
Gender, n. (%) 0.78
Men 13 (32) 5 (36)
Women 28 (68) 9 (64)
Total IgE (kUA/L) 482.17 (222.47e827.04) 149.31 (77.00e418.17) 0.04
FEV1 (L) 2.60 (2.42e2.91) 2.46 (1.85e2.83) 0.29
FEV1 (%, predicted) 81.3 (76.7e86.5) 79.3 (72.6e89.8) 0.06
DP, Dermatophagoides pteronyssinus; FEV1, forced expiratory volume in 1 s.
Results are expressed as medians with interquartile range or as absolute numbers
with percentages.AUCs for the levels of IgE Abs to nDer p 1 and rDer p 2 were 0.913
(95% conﬁdence interval (CI), 0.817e1.000) and 0.906 (95% CI,
0.801e1.000), respectively, comparable to that for DP (0.920; 95%
CI, 0.828e1.000).
Fig. 3B shows the relationship between the levels of IgE Abs and
IAR positivity predicted using a logistic regression model. The
curves show ascending slopes in which an increasing IgE concen-
tration value corresponds to a higher probability of IAR positivity.
Table 2 shows diagnostic values of IgE Abs to crude DP, nDer p 1, and
rDer p 2 at different cut-off points. IgE Abs to crude DP showed
good diagnostic values at the cut-off point of 3.5 kUA/L. However,
with the cut-off point at 0.7 kUA/L, the speciﬁcity of IgE to crude DP
was low (29%). IgE to nDer p 1 and rDer p 2 showed good diagnostic
values even at cut-off points of 0.35 and 0.70 kUA/L, demonstrating
higher speciﬁcity than crude DP.Discussion
The aim of this study was to analyze the diagnostic efﬁciency of
levels of IgE Abs to nDer p 1 and rDer p 2 as predictors of IAR after
BP. ROC analysis showed comparable AUCs for IgE Abs to nDer p 1,
rDer p 2, and crude DP while the pure allergen components dis-
played higher diagnostic speciﬁcity than the natural allergen
extract. These ﬁndings support the clinical usefulness of measuring
the levels of IgE Abs to Der p 1 and Der p 2 as a diagnostic tool for
genuine HDM allergy.
Sensitization to an allergen does not always indicate a clinically
relevant relationship between allergen exposure and the occur-
rence of allergen-speciﬁc allergic symptoms. In this study, we
considered the results of BP using allergen aerosol as an indicator of
a clinically relevant relationship between allergen exposure and
allergic symptoms, and examined the diagnostic performance of
IgE Abs to allergen components using IAR positivity as an outcome
variable. To the best of our knowledge, this is the ﬁrst report on the
association between the levels of IgE Abs to HDM allergen com-
ponents and allergen-speciﬁc airway reactivity determined by the
BP test. Although BP is not a routine procedure, it is a highly rele-
vant test in the diagnosis of respiratory allergy and useful in the
case of uncommon, newly identiﬁed, or occupationally encoun-
tered allergens.37 When allergen immunotherapy for the treatment
of allergic asthma is considered, the selection of allergens may be
guided by positive results in BP. This is considered to be the most
Fig. 2. Correlations between the levels of IgE Abs to nDer p 1 and crude DP (A), rDer p 2 and crude DP (B), rDer p 10 and crude DP (C), nDer p 1 and rDer p 2 (D), and nDer p 1 þ rDer
p 2 (sum of the levels of IgE Abs) and crude DP (E). Closed circles, IAR-positive patients; open circles, IAR-negative patients. The coefﬁcients of correlation between variables are also
shown in each ﬁgure.
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reactivity.
Der p 1 and Der p 2 are major DP allergens and sensitization to
Der p 1 and/or Der p 2 is considered to be a hallmark of genuine
Dermatophagoides sensitization.29,38 In contrast, an IgE response to
crude DP but not to Der p 1 or Der p 2 can occur in patients with a
primary sensitization to another allergen source, not necessarilyFig. 3. Receiver operating characteristic curves (A) and ﬁtted predicted probability curves (B
from DP with IAR positivity after bronchoprovocation. AUC, area under the curve; CI, conﬁassociated with HDM allergy. In this study, half (n ¼ 6) of the pa-
tients with low levels of IgE Abs to crude DP (<3.5 kUA/L) tested
negative to both nDer p 1 and rDer p 2. As these patients displayed
no IAR to HDM, we consider measurements of IgE Abs to nDer p 1
and rDer p 2 to be particularly relevant and informative for patients
showing low levels of IgE Abs to crude DP. While the identities of
the determinants causing the positive crude DP test results in these) showing the relationship of the levels of IgE Abs to crude DP and allergen components
dence interval.
Table 2
Diagnostic values of IgE to crude DP and allergen components at different cut-off
points as predictor of IAR.
Sensitivity (%) Speciﬁcity (%)
Crude DP (kUA/L)
0.35y 100 7
0.70 100 29
3.50 98 79
17.5 66 93
nDer p 1 (kUA/L)
0.35 100 43
0.70 100 64
3.50 78 79
17.5 61 93
rDer p 2 (kUA/L)
0.35 100 57
0.70 100 64
3.50 88 79
17.5 61 93
y Interpretation of values in this line is limited because only one patient showed
IgE <0.35 kUA/L to crude DP.
T. Minami et al. / Allergology International 64 (2015) 90e9594patients are presently unknown, Der p 10 can safely be excluded
based on the measurements performed in this study. We also
measured IgE Abs to cockroach (i6), moth (i8), Acarus siro (d70),
Lepidoglyphus destructor (d71), and Tyrophagus putrescentiae (d72)
in these patients to explore possible cross-reactivity between DP
and these arthopods. However, only two of the patients showed
positive results to any of these allergen sources (IgE to i6, i8, d70,
d71 and d72 in one patient, 0.42, 2.80, <0.35, <0.35 and 0.36, and in
the other patient, 1.03, 2.78, 1.17, 0.49 and 1.40 kUA/L, respectively).
One previous study has evaluated the performance of IgE to
microarrayed Der p 1 and/or Der p 2 as a predictor of HDM allergy
determined on the basis of allergen-speciﬁc histories.30 The AUC of
IgE Abs to microarrayed DP-allergen components was 0.808, which
was lower than that of IgE Abs to crude DP as determined using
ImmunoCAP system (AUC, 0.911) although the difference between
these AUCs did not reach statistical signiﬁcance. Additionally, only
69% of the patients with HDM allergy were positive for IgE Abs to
microarrayed DP-allergen components. However, in our study, AUC
of IgE Abs to crude DP and DP-allergen components were not
different, and all of the IAR-positive patients were sensitized to Der
p 1 and Der p 2. One reason for the difference in ﬁndings between
these studies was supposed to be related to the difference in the
deﬁnition of HDM allergy. The reliability and speciﬁcity of HDM
allergy diagnosis can be increased by basing the diagnosis on both
the positive reaction after BP using a DP extract and case histories.
Another reason for this was that themeasurements of IgE Abs in the
two studies are not fully comparable as the present study was
conducted entirely using ImmunoCAP, which is a more sensitive
method than microarrays.27
The main limitation of this study is related to the recruitment of
subjects. The indication of the BP for each patient was determined
according to clinical relevance, rather than predeﬁned inclusion
criteria, which may be related to the generality of our ﬁndings and
applicability to other patient populations. Another limitation was
that we have not evaluated the association between the levels of
IgE Abs and the threshold of allergen concentration in the BP test,
that is the allergen concentration producing a 20% fall in FEV1
(allergen PC20). A study has shown that IgE to crude DP is the main
determinant of allergen PD20 after BP using crude DP extract.39
However, we were unable to accurately calculate allergen PC20 in
our study, because the stepup of allergen concentrations in the BP
test in our study was not 2-fold, which is recommended in the
literature.40
In conclusion, this study showed that IgE to nDer p 1 and/or rDer
p 2 was highly predictive of IAR after BP using DP aerosol. Theoutcome of the BP test using crude DP was largely dependent on
the levels of speciﬁc IgE Abs to these DP-allergen components.
Measurement of IgE Abs to nDer p 1 and/or rDer p 2 is a useful tool
and these tests may replace crude DP for the diagnosis of genuine
HDM allergy, providing for higher diagnostic speciﬁcity.
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